Umit Tapan, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

MD, Hacettepe University

Dr. Umit Tapan is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine and practicing Thoracic Oncologist at Boston Medical Center. His clinical interests are Non-small cell lung cancer, Small cell lung cancer, Mesothelioma, Immunotherapy, Targeted therapy/Precision Medicine. His research interests include Circulating tumor DNA, Gut microbiome and Cancer Immunotherapy, Racial Disparities in Cancer Care and Outcomes.

Dr. Tapan completed his fellowship in Hematology & Oncology at Boston Univesity Medical Center, in which he was Chief Fellow in Hematology & Oncology. Dr. Tapan completed his internship and residency at Steward Carney Hospital. He earned his medical degree from Hacettepe University School of Medicine, Ankara, Turkey.

Diversity, Equity, Inclusion and Accessibility

I am honored to be working with my colleagues in providing exceptional care without exception. I have dedicated my research efforts to improving access to state-of-the art testing (also called "molecular profiling") and innovative treatments (including immunotherapy and personalized medicine) in lung cancer patients. I am an international medical graduate and I have been welcomed by the multicultural environment in the United States since my arrival in 2009. I strive to improve my understanding of the diverse cultures and backgrounds, in healthcare and in the society at large. Furthering the efforts to reduce disparities in lung cancer care, I have joined a National Thoracic Cancer Clinical Trial Working Group, with the goal of increasing enrollment of diverse patient populations to the clinical trials.

Boston University
BU-BMC Cancer Center

Boston University
Evans Center for Interdisciplinary Biomedical Research

LCMC LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
01/22/2024 - 01/21/2027 (PI)
Lung Cancer Research Foundation

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
12/15/2023 - 12/14/2026 (PI)
Janssen Research and Development, LLC

10/25/2023 - 10/24/2026 (PI)
Genentech, Inc.

07/20/2023 - 07/19/2026 (PI)

07/06/2023 - 07/05/2026 (PI)

SKY06/ BO42592:A Phase II/III, Randomized, Double-blind, Placebo-controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients with Pre
09/29/2022 - 09/28/2025 (PI)
Genentech, Inc.

DF/HCC- 19-523: Pilot study of serial plasma genotyping to guide the adaptive treatment of advanced NSCLC receiving immunotherapy.
09/02/2020 - 09/01/2024 (PI)
Dana Farber Cancer Institute

Janssen 73841937NSC1001: An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody i
02/12/2021 - 09/30/2023 (PI)
Janssen Research and Development, LLC

MS200095-0031: A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib
09/30/2020 - 09/29/2023 (PI)
EMD Serono Research & Development Institute


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Burns L, Tukachinsky H, Raskina K, Huang RSP, Schrock AB, Sands J, Kulke MH, Oxnard GR, Tapan U. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma. Lung Cancer. 2024 Feb; 188:107454.View Related Profiles. PMID: 38159439
  2. Dudipala H, Burns L, Jani CT, Radwan A, Al Omari O, Patel M, Kilic S, Zhao J, Mak K, Suzuki K, Tapan U. Disparities in Lung Cancer Clinical Trial Discussion and Enrollment at a Safety Net Hospital. Community Health Equity Res Policy. 2023 Dec 12; 2752535X231221394.View Related Profiles. PMID: 38087807
  3. Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 Dec; 186:107423.View Related Profiles. PMID: 37995456
  4. Kilic S, Zhao J, Okut H, Jani CT, Radwan A, Dudipala H, Burns L, Tapan U. Disparities in US Lung Cancer Clinical Trial Enrollment. J Racial Ethn Health Disparities. 2023 Aug 31.View Related Profiles. PMID: 37651069
  5. Al Omari O, Jani C, Ahmed A, Singh H, Radwan A, Bhatt P, Walker A, Agarwal L, Goodall R, Shalhoub J, Marshall DC, Thomson CC, Salciccioli JD, Tapan U. Lung Cancer Mortality in the United States between 1999 and 2019: An Observational Analysis of Disparities by Sex and Race. Ann Am Thorac Soc. 2023 Apr; 20(4):612-616. PMID: 36476451; PMCID: PMC10112410; DOI: 10.1513/AnnalsATS.202206-510RL;
  6. Qureshi MM, Kam A, Suzuki K, Litle V, Tapan U, Balasubramaniyan R, Dyer MA, Truong MT, Mak KS. Association between hospital safety-net burden and receipt of trimodality therapy and survival for patients with esophageal cancer. Surgery. 2023 May; 173(5):1153-1161.View Related Profiles. PMID: 36774317
  7. Siddiqi N, Pan G, Liu A, Lin Y, Jenkins K, Zhao J, Mak K, Tapan U, Suzuki K. Timeliness of Lung Cancer Care From the Point of Suspicious Image at an Urban Safety Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):e87-e93.View Related Profiles. PMID: 36642641
  8. Liu A, Siddiqi N, Tapan U, Mak KS, Steiling KA, Suzuki K. Black Race Remains Associated with Lower Eligibility for Screening Using 2021 US Preventive Services Task Force Recommendations Among Lung Cancer Patients at an Urban Safety Net Hospital. J Racial Ethn Health Disparities. 2023 Dec; 10(6):2836-2843.View Related Profiles. PMID: 36441493
  9. Burns L, Jani C, Radwan A, Omari OA, Patel M, Oxnard GR, Tapan U. Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):e69-e77.View Related Profiles. PMID: 36464575
  10. Edwards CV, Sheikh AR, Dennis MJ, Hunter A, Mackay ZP, Catudal EC, Elias R, Cabral HJ, Sarosiek SR, Tapan U. The impact of substance use on health care utilization, treatment, and outcomes in patients with non-small cell lung cancer. J Thorac Dis. 2022 Oct; 14(10):3865-3875.View Related Profiles. PMID: 36389291; PMCID: PMC9641327; DOI: 10.21037/jtd-21-1992;
Showing 10 of 34 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 34 publications over 14 distinct years, with a maximum of 6 publications in 2022 and 2023

Contact for Mentoring:
Tapan's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department